Cancer Research · asia
Seeking a Way to Target Cancer Through Ascites: Nanobody E8 Inhibits Tumors in Preclinical Models
Proteins in ascites may help sustain cancer cell growth. A Singapore team identified therapeutic clues from 397 samples and developed a nanobody targeting PAI-1; further evidence of long-term safety is still needed before human trials.
When cancer spreads to the peritoneum, fluid accumulating in the abdominal cavity is more than a consequence of disease; it may also provide an environment that supports tumor growth. A Singapore research team examined this ascitic fluid to identify proteins that could be targeted by drugs. Using the experimental nanobody E8, the team obtained evidence of tumor inhibition in cell, mouse, and ex vivo human tissue models. The findings offer a new therapeutic direction, but have not yet demonstrated benefits for patients.
The study was published in Molecular Cancer on September 11, and the National Cancer Centre Singapore announced development progress on October 19. Collaborating institutions included the Institute of Molecular and Cell Biology at Singapore’s Agency for Science, Technology and Research, Singapore General Hospital, and the National University of Singapore’s Yong Loo Lin School of Medicine. The research focused on how the fluid environment surrounding tumors in patients with peritoneal metastases affects cancer cell survival.
The team analyzed 397 malignant ascites samples from 300 patients, spanning 21 tissue origins, examining the proteins remaining after cells were removed. Integrating proteomic and gene expression data identified PAI-1 and S100A10 as potential therapeutic targets. Both are involved in regulating fibrin breakdown, prompting the researchers to ask whether these molecules, which normally participate in physiological regulation, also help tumors grow in ascites.
To trace their sources, the researchers also performed single-cell analysis on a total of 20 ascites and matched tumor samples from 10 patients. They found that distinct fibroblast populations may contribute to the production of the two proteins, respectively. This provided a more specific cellular context for the signals in ascites and suggested that treatment design requires an understanding of interactions between cancer cells and surrounding cells.
The team chose PAI-1 as the target for developing nanobody E8, a smaller antibody fragment. E8 showed tumor-inhibiting activity across multiple preclinical models. In one model, ex vivo human tumor tissue was cultured in patient ascites, and tumor viability decreased after E8 was added. Such models retain some characteristics of human tissue, but cannot fully reproduce drug distribution, immune responses, or long-term exposure in patients.
The low toxicity reported in the study and the institutional announcement should also be understood within this scope. The paper’s authors explicitly stated that further toxicity studies involving repeated dosing and different time scales are needed to assess cumulative effects. Because PAI-1 also contributes to normal tissue function, the effects of inhibiting it on coagulation, fibrin breakdown, and wound healing also need to be examined.
According to the National Cancer Centre Singapore announcement, E8 has become the lead drug candidate in the Melyorax Initiative biologics research program led by Johnny Ong, and is advancing toward clinical-grade development and first-in-human trials. The team is also developing an accompanying biomarker test to detect elevated PAI-1, hoping to help select patients who may benefit. Whether this strategy is viable must next be answered in human trials: can molecular clues in ascites translate into a tolerable and effective treatment?